Quest Diagnostics Incorporated reports developments in diagnostic information services, laboratory testing and related healthcare data offerings. Company news commonly covers financial results, guidance, clinical testing activity, consumer access through questhealth.com and MyQuest, and advanced diagnostics such as Quest AD-Detect blood tests for Alzheimer’s disease and Haystack MRD ctDNA testing for oncology research.
Updates also include health system collaborations, Co-Lab Solutions activity, clinical trial and research partnerships, AI-enabled patient tools, board and executive appointments, dividends, share repurchases, debt financing and shareholder voting matters.
Quest Diagnostics (NYSE: DGX) announced that Executive Vice President & Chief Financial Officer Sam Samad will discuss the company’s strategy, performance and market trends at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on Monday, September 14, 2026, at 10:00 a.m. Eastern Time. The fireside chat and Q&A will be webcast live on the company’s investor relations website, with an archived replay available within 24 hours and accessible until October 12, 2026, according to Quest Diagnostics.
Quest Diagnostics (NYSE: DGX) announced two expansions to its Quest AD-Detect® blood-based biomarker portfolio for assessing Alzheimer's disease in symptomatic patients. Quest plans to offer an AD-Detect-branded laboratory test based on Roche's newly FDA-cleared Elecsys® pTau217 assay nationwide in the fourth quarter, and to integrate this test into future AD-Detect panels in 2027.
Separately, Quest will launch at month-end a new multi-biomarker AD-Detect® lab-developed test combining ABeta 42/40, p-tau217 and ApoE evaluation. According to Quest, published research shows this test aligns with Alzheimer Association guideline thresholds and achieved a 10% indeterminate rate, below the 15–20% rate recommended by the Global CEO Initiative on Alzheimer's Disease.
Quest Diagnostics (NYSE: DGX) powers WHOOP Advanced Labs in the U.S., which WHOOP is now offering without requiring a wearable membership and is expanding to include GRAIL’s Galleri multi-cancer early detection blood test.
Advanced Labs provides comprehensive blood panels reviewed and ordered by licensed healthcare providers, covering cardiovascular, metabolic, hormonal, and inflammatory health. According to WHOOP, testing starts at about $150, notably below costs it compares to traditional settings, and is available via a single blood draw at nearly 2,000 Quest locations, with clinician-reviewed results and guidance delivered through the WHOOP app.
Quest Diagnostics (NYSE: DGX) announced that its Board of Directors has declared a quarterly cash dividend of $0.86 per share.
The dividend is payable on October 21, 2026, to shareholders of record of Quest Diagnostics common stock as of October 6, 2026.
Quest Diagnostics (NYSE: DGX) reported results from a Health Trends study with Hologic analyzing deidentified molecular test data from over 1.5 million U.S. women (2022–2024), published in O&G Open. Overall, 38.7% tested positive for bacterial vaginosis (BV) and 28.5% for vulvovaginal candidiasis; 10.8% had both.
Among BV‑positive women, 12.0% had at least one non‑viral STI versus 3.8% of BV‑negative women. After adjustment, BV positivity was associated with higher odds of chlamydia (2.8x), gonorrhea (3.8x), trichomonas (3.6x) and Mycoplasma genitalium (1.9x). Candidiasis alone was not associated with increased STI risk. Quest noted the large, nationally representative sample as a strength, and single‑lab, limited patient data as key limitations, and highlighted its 2024 rollout of self‑collection services for BV and related infections.
Quest Diagnostics (NYSE: DGX) reported second quarter 2026 net revenues of $3.04 billion, up 10.2% year over year, driven by 10.0% organic revenue growth and a 13.1% increase in requisition volume. Diagnostic Information Services revenues rose 10.3%.
Reported diluted EPS was $2.84, up 15.0%, while adjusted diluted EPS was $3.12, up 19.1%. Operating cash flow for the quarter was $597 million, up 9.7%. The company raised its 2026 guidance, now expecting net revenues of $11.95–$12.05 billion, reported diluted EPS of $9.97–$10.17, and adjusted diluted EPS of $11.05–$11.25. Expected 2026 cash from operations was increased to approximately $1.80 billion, with capital expenditures unchanged at about $550 million.
Quest Diagnostics (NYSE:DGX) reported that 19.1% of general U.S. workers tested via hair in 2025 were drug-positive, up from 13.1% in 2021, according to its 2026 Drug Testing Index. Marijuana hair positivity reached 15.1%, a 58.9% increase over five years and 52.5% of all hair positives.
Overall urine drug positivity in the workforce was 4.3% in 2025, slightly below 4.4% in 2024 but above 4% for more than a decade. Marijuana positivity was 4.4% in urine, 11.1% in oral fluid, and 15.1% in hair. Healthcare showed the highest industry positivity at 5.8%, with retail trade and professional and technical services also elevated. Fentanyl positivity in the general workforce declined 49.1% year over year, from 0.55% in 2024 to 0.28% in 2025.
Quest Diagnostics (NYSE: DGX) is integrating its Haystack MRD ctDNA test and Comprehensive Genomic Profiling for solid tumors into Flatiron Health's OncoEMR MPI via a pilot with American Oncology Network and other community practices.
The integration aims to simplify molecular test ordering and results for up to 4,700 clinicians across 1,600 cancer care locations nationwide in the second half of the year.
Quest Diagnostics (NYSE:DGX) received New York State Department of Health CLEP approval for its Haystack MRD ctDNA liquid biopsy test to identify residual or recurring disease in a range of solid tumor cancers.
With this authorization, Haystack MRD is now available for patient testing in all 50 U.S. states, supported by published clinical data showing it identified clinical complete response at a median of 1.4 months versus over 6 months with imaging.
Quest Diagnostics (NYSE:DGX) and Hackensack Meridian CDI reported a nationwide study in Nature Communications on multidrug-resistant Klebsiella pneumoniae causing community urinary tract, pneumonia and wound infections.
The study analyzed 2,000+ U.S. samples, finding 100% multidrug resistance and 69.5% non-susceptibility to three leading oral UTI antibiotics.